Welcome to our dedicated page for StageWise Strtgs SEC filings (Ticker: STWI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on StageWise Strtgs's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into StageWise Strtgs's regulatory disclosures and financial reporting.
StageWise Strategies Corp. reported weak results for the three months ended December 31, 2025. Revenue was $19,219, down sharply from $54,690 a year earlier, and the company recorded a net loss of $14,243 versus prior net income of $27,700.
Cash and cash equivalents were just $516 as of December 31, 2025, against current liabilities of $233,894, including a related-party loan balance of $206,700. Stockholders’ equity was negative at $(91,277), with an accumulated deficit of $126,607, and management prepared the statements on a going concern basis, noting reliance on future funding and increased sales.
During the quarter, the CEO voluntarily cancelled 1,000,000 common shares without consideration, reducing outstanding shares to 4,044,334. The company highlighted material weaknesses in disclosure controls and internal control over financial reporting, and appointed Anna Toczko to the Board of Directors.